Tada......what you really mean is, 'thanks for not fixating on the lousy communication from the company' :-)

I almost sent another email to IR....its been 2 months since they announced agreeing to changing the BETonMACE protocol, but we still don't know what the changes are.  One thing I hadn't noted before was the language of the Subject of that PR....

Resverlogix Receives Approval Pathway from the FDA as to the Inclusion of USA Patients in the Phase 3 BETonMACE Trial

"Approval Pathway".....I had been operating under the assumption that USA patients were approved, and based on an email from Clayton that it was simply a matter of the steering comittee agreeing to some adjustments to the BETonMACE study protocol.  

But now I'm thinking that the Type C written response was simply about this "pathway".....as in maybe something like this:

For BETonMACE to receive approval to dose USA patients the following adjustments must be made to the study...a/b/c/d. After completion of the aforementioned adjustments application can be made for review at which point a determination will be made.  

It seems to me that if they had a full green light to dose USA patients....2 months seems enough time.